What Are the Top Biktarvy Alternatives for HIV?

Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) is one of the most widely prescribed HIV treatments in the world, and for good reason: five-year data show that roughly 99% of treatment-naive people who took it maintained an undetectable viral load.¹ But “extremely effective” does not mean “right for everyone.” Side effects, drug interactions, pregnancy plans, cost, injection-site reactions from a different regimen that a person wants to leave, or simply the psychological burden of a daily pill can all be legitimate reasons to explore something else. Several alternatives now exist, from other single-tablet regimens to long-acting injectables given every month or two.

Why People Look for Alternatives

Most people who start Biktarvy do well on it. The reasons for switching or choosing a different regimen in the first place tend to fall into a few categories. Some people experience weight gain or metabolic changes they find unacceptable. Others develop neuropsychiatric symptoms like insomnia or mood disturbance that they suspect are linked to the integrase inhibitor class. Pregnancy is another consideration, since Biktarvy lacks the safety data in pregnant women that other regimens have accumulated. And a growing number of people are interested in moving away from daily pills altogether, in favor of injections that happen on a less frequent schedule.

Cost matters too, particularly in health systems outside the United States. Biktarvy has no generic equivalent in most markets, and its price tag can push clinicians and patients toward regimens built from generic components. Whatever the motivation, the decision should always involve a clinician who can review your resistance profile, kidney function, other medications, and personal priorities.

Dolutegravir Plus Lamivudine as a Two-Drug Option

One of the most established alternatives is the combination of dolutegravir and lamivudine, available as the single pill Dovato. This is a two-drug regimen rather than the traditional three-drug approach, which appeals to people who want to minimize their long-term drug exposure. A large meta-analysis of real-world studies found that among people starting treatment for the first time, about 96% achieved viral suppression at 48 weeks, with virologic failure occurring in fewer than 1% of cases.² Among people switching from a prior regimen, suppression rates were similarly high at both 48 and 96 weeks.³ Both dolutegravir/lamivudine and Biktarvy are considered first-line treatments worldwide.⁴

There are important caveats. Dolutegravir/lamivudine is not recommended if you have hepatitis B co-infection, because lamivudine alone does not provide adequate hepatitis B coverage (Biktarvy’s tenofovir alafenamide component does). It is also not appropriate for people who already carry certain resistance mutations or who have a viral load above 500,000 copies per milliliter at the start of treatment. If neither of those applies to you, it is a well-supported alternative with the advantage of exposing your body to one fewer drug.

Long-Acting Cabotegravir Plus Rilpivirine

For people who are already virally suppressed and want to stop taking daily pills, the injectable combination of cabotegravir and rilpivirine (brand name Cabenuva) is a genuine game-changer. After a brief oral lead-in period to check tolerability, you switch to intramuscular injections given every one or two months by a healthcare provider. A phase 3b trial comparing this injectable regimen to continued Biktarvy found that the two were equally effective at maintaining viral suppression, with about 1% of the injectable group and fewer than 1% of the Biktarvy group having detectable virus at the end of the study period.⁵

The patient experience data tell a striking story. In the same trial, 90% of people who switched to the injections preferred them over Biktarvy, and treatment satisfaction scores rose significantly in the injectable group while they actually fell slightly in the group that stayed on Biktarvy.⁶ People on the injections reported less anxiety about adherence, less fear of disclosure, and less feeling that taking a daily pill was a constant reminder of their HIV status.⁷

The trade-off is injection-site reactions. About 70% of people in the injectable group reported them, though nearly all were mild (grade 1 or 2), meaning soreness or tenderness that resolved on its own.⁸ About 6% of the injectable group withdrew due to adverse events, compared with 1% in the Biktarvy group.⁹ You also need reliable access to a clinic for each injection; missing a scheduled dose with a long-acting regimen can have consequences for resistance that are harder to manage than missing a pill or two.

A Protease Inhibitor-Based Single Pill

If integrase inhibitors as a class are not working for you, whether due to resistance, side effects, or a clinician’s preference, Symtuza (darunavir/cobicistat/emtricitabine/tenofovir alafenamide) is the main single-tablet alternative built around a different drug class. It combines the protease inhibitor darunavir with a pharmacokinetic booster (cobicistat) and the same two backbone drugs used in many other regimens.¹⁰

Darunavir has a high genetic barrier to resistance, meaning the virus needs to accumulate many mutations before it can escape the drug’s control. That makes Symtuza a particularly strong choice for people with complicated treatment histories or partial resistance to other drug classes.¹¹ In phase 3 trials, it was noninferior to continued boosted protease inhibitor regimens in people who were already suppressed, and resistance to the darunavir component essentially did not emerge.¹²

The downside of boosted protease inhibitors is drug interactions. Cobicistat inhibits liver enzymes that metabolize a wide range of other medications, so if you take drugs for high cholesterol, seizures, heart rhythm, or certain psychiatric conditions, your clinician will need to check for conflicts carefully. This is one of Biktarvy’s advantages by comparison: bictegravir has fewer drug-drug interactions than boosted protease inhibitors, though it is not interaction-free either.

Doravirine-Based Regimens

Doravirine is a newer non-nucleoside reverse transcriptase inhibitor (NNRTI) that avoids many of the problems associated with older drugs in its class, like efavirenz, which was notorious for vivid dreams, dizziness, and mood disturbance. Doravirine is available as the single pill Delstrigo (doravirine/lamivudine/tenofovir disoproxil fumarate) or as a standalone tablet combined with other backbone drugs.

One reason doravirine attracts attention as a Biktarvy alternative is weight. Integrase inhibitors, including bictegravir, have been linked to weight gain in some patients. Research on doravirine suggests it is generally weight-neutral. A study looking at people who continued or switched to doravirine found that over half maintained stable weight, and that switching to doravirine was overall weight-neutral, though individual results varied by demographic factors and the weight-suppressive properties of whatever regimen a person was switching from.¹³ A separate real-world study in Belgrade found no significant short-term changes in triglycerides, total cholesterol, or LDL cholesterol among people taking a doravirine-based regimen.¹⁴

There is an important limitation: doravirine, like all NNRTIs, has a lower barrier to resistance than integrase inhibitors or boosted protease inhibitors. If you have any pre-existing NNRTI resistance mutations, doravirine may not be a reliable option, and your provider will want to check your resistance genotype before prescribing it.

Lenacapavir for Multidrug-Resistant HIV

Lenacapavir (brand name Sunlenca) occupies a different niche entirely. It is a capsid inhibitor, a drug class that works by a mechanism distinct from all four traditional classes of antiretrovirals. It was specifically developed for people whose virus has developed resistance to multiple drug classes, a situation where Biktarvy and most standard alternatives are no longer effective.

In its pivotal phase 3 trial, lenacapavir was given to 72 patients with multidrug-resistant HIV. After two weeks, 88% of those receiving lenacapavir had at least a half-log drop in viral load, compared with 17% on placebo. By 26 weeks, about 81 to 83% of participants had reached an undetectable viral load.¹⁵ That is a remarkable result in a population that had run out of options. Lenacapavir is administered as a subcutaneous injection every six months, which is the longest dosing interval of any current HIV treatment.¹⁶

Lenacapavir is not a direct swap for Biktarvy in the way that Dovato or Cabenuva might be. It is currently approved for people with multidrug resistance, and it is used in combination with other antiretrovirals chosen to build the best possible regimen from whatever agents the person’s virus remains sensitive to. Research into lenacapavir’s use in broader treatment populations is ongoing, but for now it represents a lifeline for people who genuinely have no standard options left.

Pregnancy and Family Planning

If you are pregnant or planning to become pregnant, your choice of regimen matters in ways that go beyond your own health. Biktarvy is currently not recommended during pregnancy because of limited data on its safety for the developing fetus and its effectiveness at preventing vertical transmission.¹⁷ The integrase inhibitors that do have substantial pregnancy data are dolutegravir and raltegravir, both of which are considered effective and safe during pregnancy.¹⁸

This is a concrete scenario where switching off Biktarvy is not a matter of preference but of clinical guidance. If you are on Biktarvy and planning pregnancy, discuss a transition to a dolutegravir- or raltegravir-based regimen with your provider well before conception. The key is to make the switch early enough that you are virally suppressed on the new regimen before pregnancy begins.

Neuropsychiatric Side Effects and Switching Between Integrase Inhibitors

Integrase inhibitors as a class have been associated with neuropsychiatric side effects in some people: insomnia, anxiety, depression, and difficulty concentrating. These symptoms show up more often with dolutegravir than with bictegravir, though bictegravir is not immune to them. A randomized trial found that switching from dolutegravir-based treatment to Biktarvy was associated with improvement in sleep disorders, though other neuropsychiatric symptoms did not change significantly.¹⁹

For people who find Biktarvy itself causes these symptoms, the alternative may be to move to a non-integrase regimen altogether, such as a doravirine-based combination or the protease inhibitor-based Symtuza. In a study of people switching from the older NNRTI efavirenz to Biktarvy, few central nervous system adverse events were observed, and those that occurred were mild: a handful of cases of insomnia and headache out of 126 participants.²⁰ That study essentially showed Biktarvy being a solution for efavirenz-related brain fog, but it also suggests that when Biktarvy itself is the problem, you may need to exit the integrase inhibitor class to find relief.

When You Have Pre-Existing Resistance Mutations

A common clinical scenario is someone who developed the M184V/I resistance mutation on a previous regimen. This mutation confers resistance to both emtricitabine and lamivudine, two drugs found in many first-line regimens including Biktarvy. You might assume this makes Biktarvy a poor choice, but pooled data from multiple studies showed that 98% of people carrying M184V/I who switched to Biktarvy maintained viral suppression, with no new resistance to any Biktarvy component emerging.²¹ That rate was statistically indistinguishable from the 99% suppression rate among people without the mutation.²²

This is relevant to people considering alternatives: if you are being told you need to leave Biktarvy because of M184V/I, the data suggest you probably do not. However, broader resistance patterns that affect the integrase inhibitor class itself (rare with bictegravir, but possible) are a different story and may necessitate a regimen built around a protease inhibitor or, in extreme cases, lenacapavir.

Cost and the Case for Multi-Tablet Regimens

Biktarvy is expensive. In many countries, it carries one of the highest price tags of any single-tablet HIV regimen, and no generic version is available in most markets. For health systems under budget pressure, splitting a branded single-tablet regimen into its individual generic components is an appealing strategy. A French study found that switching from the single-tablet combination of abacavir/lamivudine/dolutegravir to separate generic pills could save about 2,400 euros per patient per year, with similar savings available for other regimens.²³

The trade-off is adherence. Taking one pill instead of two or three is consistently associated with better adherence, and modeling has shown that single-tablet regimens are cost-effective over a patient’s lifetime when you account for reduced hospitalizations and better outcomes. One U.S. analysis estimated that single-tablet regimens produced an additional 0.6 quality-adjusted life years per patient compared to multi-tablet generic regimens, at an incremental cost-effectiveness ratio that falls well within what health systems typically consider worthwhile.²⁴ In other words, the single pill costs more upfront but may save money downstream by keeping people healthier. Whether that math applies to any individual patient depends on their insurance, their country’s pricing, and how confident they are in their own adherence.

The Doravirine-Islatravir Combination on the Horizon

One emerging alternative worth knowing about is the combination of doravirine and islatravir, a once-daily single pill that would be the first two-drug regimen not built around an integrase inhibitor. Islatravir is a nucleoside reverse transcriptase translocation inhibitor, a new mechanism that works differently from existing drugs in its broader class. A phase 3 trial found the combination efficacious and well tolerated in people switching from Biktarvy.²⁵

Why does this matter? The entire first-line landscape of HIV treatment currently leans heavily on integrase inhibitors. If widespread integrase inhibitor resistance develops over the coming decades, the field will need viable non-integrase options. Doravirine-islatravir could fill that gap while also offering a reduced pill burden compared to traditional three-drug NNRTI regimens.²⁶ Islatravir also has long-acting potential, raising the possibility of future formulations that could be dosed weekly or even less frequently. The combination is not yet approved, but the data so far position it as a serious contender once it reaches the market.

How Drug Interactions Differ Across Alternatives

One practical factor that does not get enough attention is how different regimens interact with other medications. This matters most for older adults living with HIV, who often take drugs for blood pressure, cholesterol, diabetes, or depression alongside their antiretroviral therapy. All five approved integrase inhibitors (raltegravir, elvitegravir, dolutegravir, bictegravir, and cabotegravir) share a mechanism of action but differ in how they are metabolized, leading to different drug-drug interaction profiles.²⁷

Biktarvy’s bictegravir has relatively few interactions compared to boosted regimens, but it can still interact with certain antacids, supplements containing calcium or iron, and some anti-seizure medications. If your medication list is long and complex, your clinician may prefer a regimen where every interaction has been well-characterized over years of use. In some cases, the older protease inhibitor darunavir (in Symtuza) is actually easier to manage because its interactions, while numerous, are thoroughly documented and predictable. In other cases, doravirine’s clean interaction profile makes it the better fit. There is no universal winner here; the best choice depends on the specific combination of drugs you take.